FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W160520817> ?p ?o ?g. }

• W160520817 endingPage "657" @default.
• W160520817 startingPage "649" @default.
• W160520817 abstract "Objective: This study examines the outcomes of de novo kidney transplants treated by a sequential protocol, designed to target the succession of immunologic events following engraftment. Subjects: A total of 113 sequential live-donor recipients were randomized into 2 arms. Patients in arm A received prednisolone, cyclosporine, and sirolimus for 3 months (phase 1), followed by replacement of cyclosporine with mycophenolate mofetil (phase 2). Those in arm B (controls) received prednisolone/cyclosporine/mycophenolate mofetil throughout the study. The primary endpoints were patient and graft survival rates at 2 years. Secondary endpoints included biopsy-proven acute rejection, early and late graft function, hypertension, and adverse reactions. Results: The 2-year intent-to-treat patient and graft survival rates (95.8% vs 91.4% and 94.6% vs 90.2%) were numerically but not significantly higher in arm A. The overall incidence of biopsy-proven acute rejection was numerically lower (13.5% vs 18.9%), yet it occurred exclusively with cyclosporine C2 levels below 770 ng/mL (P = .28). Mean time for serum creatinine to reach 132 µmol/L was significantly longer in arm A (7.3 vs 2.9 days). Graft function at 2 years (eGFR, 70.2 vs 55.9 mL/min) and number of drugs needed to control blood pressure (mean 1.7 vs 2.25) were significantly more favorable in group A. Significant adverse effects for patients in arm A included proteinuria (36.8% vs 18.6%), hyperlipidemia (peak cholesterol > 7.75 mmol/L in 32.9% vs 23.7% of patients) and thrombocytopenia (platelet count < 100 ! 10 9 /L in 32.9% vs 13.5 % of patients). Conclusions: The described protocol reduced the incidence of biopsy-proven acute rejection in patients after kidney transplant, particularly in those with adequate cyclosporine blood levels. Despite the significantly higher incidence of certain adverse effects (ie, delayed graft function, proteinuria, hyperlipidemia, and transient thrombocytopenia), patient and graft survival rates at 2 years were numerically, though not statistically, improved in patients in arm A. At 2-year analysis, compared with patients in the control arm (arm B), graft function significantly improved in patients in arm A, and the number of drugs needed to control blood pressure was significantly lower. Despite considerably improved outcomes during the past 2 decades, risk-free, near-normal, long-term patient survival and desirable quality of life remain elusive for persons undergoing renal transplant. The ambition to achieve these, however, has been a driving force for better understanding of transplant immunity, new drug discovery, development of new strategies, and the implementation of new protocols, all with impressive successes as well as disappointing failures." @default.
• W160520817 created "2016-06-24" @default.
• W160520817 creator A5006489388 @default.
• W160520817 creator A5017087652 @default.
• W160520817 creator A5024140190 @default.
• W160520817 creator A5024895061 @default.
• W160520817 creator A5029225592 @default.
• W160520817 creator A5037281083 @default.
• W160520817 creator A5057893621 @default.
• W160520817 creator A5065951847 @default.
• W160520817 creator A5079233562 @default.
• W160520817 creator A5090502775 @default.
• W160520817 date "2007-12-01" @default.
• W160520817 modified "2023-09-27" @default.
• W160520817 title "The Cairo kidney center protocol for rapamycin-based sequential immunosuppression in kidney transplant recipients: 2-year outcomes." @default.
• W160520817 cites W1968125610 @default.
• W160520817 cites W1969699775 @default.
• W160520817 cites W1969979548 @default.
• W160520817 cites W1975279059 @default.
• W160520817 cites W1986545689 @default.
• W160520817 cites W1991910646 @default.
• W160520817 cites W2009368147 @default.
• W160520817 cites W2010182096 @default.
• W160520817 cites W2018798721 @default.
• W160520817 cites W2027357824 @default.
• W160520817 cites W2028025188 @default.
• W160520817 cites W2030317481 @default.
• W160520817 cites W2031006751 @default.
• W160520817 cites W2035495537 @default.
• W160520817 cites W2048942752 @default.
• W160520817 cites W2053144051 @default.
• W160520817 cites W2055923362 @default.
• W160520817 cites W2058429929 @default.
• W160520817 cites W2059225925 @default.
• W160520817 cites W2066573789 @default.
• W160520817 cites W2066992691 @default.
• W160520817 cites W2072583817 @default.
• W160520817 cites W2072771705 @default.
• W160520817 cites W2077118416 @default.
• W160520817 cites W2078297196 @default.
• W160520817 cites W2081065237 @default.
• W160520817 cites W2081842582 @default.
• W160520817 cites W2092712262 @default.
• W160520817 cites W2095072078 @default.
• W160520817 cites W2106614142 @default.
• W160520817 cites W2125588437 @default.
• W160520817 cites W2126431533 @default.
• W160520817 cites W2128257213 @default.
• W160520817 cites W2128298677 @default.
• W160520817 cites W2133944572 @default.
• W160520817 cites W2139609632 @default.
• W160520817 cites W2148724358 @default.
• W160520817 cites W2163502830 @default.
• W160520817 cites W2317150139 @default.
• W160520817 cites W2415034621 @default.
• W160520817 cites W2415224885 @default.
• W160520817 cites W2417250949 @default.
• W160520817 cites W2418956629 @default.
• W160520817 cites W2911538230 @default.
• W160520817 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18194116" @default.
• W160520817 hasPublicationYear "2007" @default.
• W160520817 type Work @default.
• W160520817 sameAs 160520817 @default.
• W160520817 citedByCount "5" @default.
• W160520817 countsByYear W1605208172014 @default.
• W160520817 countsByYear W1605208172015 @default.
• W160520817 countsByYear W1605208172017 @default.
• W160520817 countsByYear W1605208172020 @default.
• W160520817 crossrefType "journal-article" @default.
• W160520817 hasAuthorship W160520817A5006489388 @default.
• W160520817 hasAuthorship W160520817A5017087652 @default.
• W160520817 hasAuthorship W160520817A5024140190 @default.
• W160520817 hasAuthorship W160520817A5024895061 @default.
• W160520817 hasAuthorship W160520817A5029225592 @default.
• W160520817 hasAuthorship W160520817A5037281083 @default.
• W160520817 hasAuthorship W160520817A5057893621 @default.
• W160520817 hasAuthorship W160520817A5065951847 @default.
• W160520817 hasAuthorship W160520817A5079233562 @default.
• W160520817 hasAuthorship W160520817A5090502775 @default.
• W160520817 hasConcept C126322002 @default.
• W160520817 hasConcept C126894567 @default.
• W160520817 hasConcept C141071460 @default.
• W160520817 hasConcept C159641895 @default.
• W160520817 hasConcept C168563851 @default.
• W160520817 hasConcept C197934379 @default.
• W160520817 hasConcept C203092338 @default.
• W160520817 hasConcept C2776715498 @default.
• W160520817 hasConcept C2777921159 @default.
• W160520817 hasConcept C2778033501 @default.
• W160520817 hasConcept C2779561371 @default.
• W160520817 hasConcept C2780091579 @default.
• W160520817 hasConcept C2780252810 @default.
• W160520817 hasConcept C2780303639 @default.
• W160520817 hasConcept C2780306776 @default.
• W160520817 hasConcept C2909935303 @default.
• W160520817 hasConcept C2911091166 @default.
• W160520817 hasConcept C71924100 @default.
• W160520817 hasConcept C90924648 @default.

• next